Last Updated: Tuesday, June 11, 2013
Principal Investigator: Jeremy M. Veenstra-VanderWeele, M.D.
Other researchers: Cassandra Newsom, PhD and Kevin Sanders, MD
Research has identified the protein MGLUR5 as a neurochemical target for reducing characteristic behavior problems in adults with Fragile X. This medication should block this protein from being used in the brain.
The purpose of this study is to assess the safety and usefulness of three doses in treating behavioral symptoms of Fragile X.
Read more about Fragile X research at Vanderbilt by clicking here.
Adolescents (12-17 years old) with Fragile X syndrome
Compensation for time and travel.
Nine visits over 20 weeks - between 1 and 3 hours in length.
Children with a confirmed diagnosis of Fragile X between 3 and 11 years.Compensation: Yes
Adults age 14– 50 with Fragile X for a study using an investigational drug.Compensation: Yes
People with Fragile X age 5-13Compensation: Yes
Children age 6– 17 with an autism spectrum disorder who are taking an atypical antipsychotic like Risperidone (risperidol), Zyprexa (Olanzapine) and have gained unwanted weight.Compensation: Yes
Children age 6-18 with autism spectrum disorders with and without GI problems.Compensation: Yes
Males ages 18-45 with diagnosis of autism spectrum disorder. Must be verbal.Compensation: Yes
Visit this investigator's people page to list all of their studies together.